

## Qsymia - ((3.75/23,7.5/46,11.25/69,15/92)mg;Capsule Extended)

<b>Generic Name</b>	Phentermine Hydrochloride and Topiramate	<b>Innovator</b>	Vivus
<b>Dosage</b>	(3.75/23,7.5/46,11.25/69,15/92)mg;Capsule Extended	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	None
<b>Indication</b>	As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of $\geq 30\text{kg/m}^2$ or $\geq 27\text{kg/m}^2$ in the presence of at least one weight related co-morbidity (eg, hypertension, type 2 diabetes, or dyslipidemia).		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.